I-01 Jeroen Elassaiss-Schaap Translational Pharmacokinetic/Pharmacodynamic Model of Tumor Growth Inhibition by the New Anti-PD1 Monoclonal Antibody MK-3475 Wednesday 10:20-11:50 |
I-02 Moran Elishmereni Improved sunitinib therapy in non-small cell lung cancer as predicted by a new mixed-effects model Wednesday 10:20-11:50 |
I-03 Yumi Yamamoto Toward a generic PBPK model to predict drug distribution in human brain Wednesday 10:20-11:50 |
I-04 Farkad Ezzet Dose Response Models for Multiple Endpoints: A Simulation Study Wednesday 10:20-11:50 |
I-05 Floris Fauchet Impact of maternal zidovudine infusions at labor on fetus: a population pharmacokinetic study Wednesday 10:20-11:50 |
I-06 Sylvain Fouliard Cardiac safety monitoring in early oncology trials using optimal design and M&S approach Wednesday 10:20-11:50 |
I-07 Tomoko Freshwater Competitive landscape model using meta-analysis and simulation-based evaluation for Phase IIb study design of MRL-1 being developed for the treatment of rheumatoid arthritis Wednesday 10:20-11:50 |
I-08 Aline Fuchs Impact of medication adherence measurement on antiretroviral drug pharmacokinetics: A retrospective cohort study in HIV patients followed by therapeutic drug monitoring and taking part in a medication-adherence enhancing program Wednesday 10:20-11:50 |
I-09 María José García Sánchez PBPK analysis of doxorrubicin tissue uptake by Simcyp® simulator: influence of gender related variables Wednesday 10:20-11:50 |
I-10 María García-Cremades Pharmacokinetic and Pharmacodynamic analysis of Gemcitabine in pancreatic cancer in mice. Wednesday 10:20-11:50 |
I-11 Marc Gastonguay Proposal for a Web-Based Open Pharmacometrics Curriculum: Results of a Four-Month Pilot Evaluation Wednesday 10:20-11:50 |
I-13 Eva Germovsek Mechanistic Modelling of Total Body CD4 T-cell Counts from Paediatric HIV Patients Undergoing Planned Treatment Interruption Wednesday 10:20-11:50 |
I-14 Ekaterina Gibiansky Population Pharmacokinetics of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL) Wednesday 10:20-11:50 |
I-15 Leonid Gibiansky Numerical Testing of Assumptions for Target-Mediated Drug Disposition (TMDD) Equations: Why Inexact Model Provides Satisfactory Description? Wednesday 10:20-11:50 |
I-16 Sandra Gil Modeling the Postantifungal Effect of Anidulafungin Against Candida Wednesday 10:20-11:50 |
I-17 Anais Glatard A model-based approach to support NOAEL determination: a simulation case illustrated by a real dataset Wednesday 10:20-11:50 |
I-18 Bojana Golubovic Population pharmacokinetics of sirolimus in adult kidney transplant patients Wednesday 10:20-11:50 |
I-19 Marta Gonzalez In-silico Biopharmaceutical Systems for Provisional Classification of Oral Drugs Wednesday 10:20-11:50 |
I-20 Ignacio Gonzalez-Garcia Simulations of populations with different creatinine clearance range and weight to select the best dose of NV22413 Wednesday 10:20-11:50 |
I-21 Mario Gonzalez Sales Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy volunteers. Wednesday 10:20-11:50 |
I-22 Isabel Gonzalez-Alvarez Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid Wednesday 10:20-11:50 |
I-23 Sathej Gopalakrishnan Assessing treatment failure under combination therapy in HIV disease Wednesday 10:20-11:50 |
I-24 Verena Gotta Power of PKPD analysis to detect QTc effect in preclinical setting Wednesday 10:20-11:50 |
I-25 Abhishek Gulati Modeling the effect of interferon beta-1b on contrast enhancing lesions in relapsing-remitting multiple sclerosis Wednesday 10:20-11:50 |
I-26 Serge Guzy Evaluation of Bias and Precision using QRPEM algorithm in Phoenix NLME for discrete data models Wednesday 10:20-11:50 |
I-27 Chihiro Hasegawa Modeling & simulation of ONO-5334, a cathepsin K inhibitor, to support dose selection in osteoporosis Wednesday 10:20-11:50 |
I-28 Michael Heathman Concentration-Response Modeling of Adverse Event Data using a Markov Chain Approach Wednesday 10:20-11:50 |
I-29 Stefanie Hennig Population pharmacokinetics of high dose methotrexate in non-Hodgkin lymphoma patients Wednesday 10:20-11:50 |
I-30 Christoph Hethey Towards a cell-level model to predict bacterial growth under antimicrobial perturbation Wednesday 10:20-11:50 |
I-31 Jules Heuberger The prior subroutine explored: pharmacokinetic modeling of THC Wednesday 10:20-11:50 |
I-32 Mistry Hitesh Virtual Tumour Clinical: translational modelling of vemurafenib, selumetinib and docetaxel inmetastatic melanoma Wednesday 10:20-11:50 |
I-33 Rollo Hoare Modelling CD4 lymphocyte reconstitution following paediatric haematopoietic stem cell transplantation Wednesday 10:20-11:50 |
I-34 Nick Holford Evaluation of NONMEM and Monolix by Parametric Bootstrap Wednesday 10:20-11:50 |
I-35 Xiao Hu Exposure-Response Analysis of Peginterferon beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis Wednesday 10:20-11:50 |
I-36 Kimberley Jackson Population Pharmacokinetic (PK) Modelling of Ketamine and Norketamine in Plasma, Prefrontal Cortex (PFC) and Cerebrospinal Fluid (CSF) after Subcutaneous (SC) Administration of S(+)-Ketamine in Rats. Wednesday 10:20-11:50 |
I-37 Bart Jacobs Model based optimization of a novel controlled release formulation of capecitabine Wednesday 10:20-11:50 |
I-38 Esther Janssen Simulations of vancomycin exposure throughout childhood upon commonly used dosing guidelines: towards a model-based dosing regimen Wednesday 10:20-11:50 |
I-39 Petra Jauslin Comparison of post-prandial glucose control by two GLP-1 receptor agonists (lixisenatide and liraglutide) in type 2 diabetes Wednesday 10:20-11:50 |
I-40 Garrit Jentsch The BAST Clinical Trial Simulator: A computational framework for quantitative risk assessment. Wednesday 10:20-11:50 |
I-41 Jin Jin Longitudinal Safety Modeling and Simulation for Regimen Optimization of Vismodegib in Operable Basal Cell Carcinoma Wednesday 10:20-11:50 |
I-42 Niclas Jonsson A Population PK Analysis of Nebivolol and Valsartan in Combination Therapy Wednesday 10:20-11:50 |
I-43 Marija Jovanovic Effect of Valproic Acid Daily Dose on Phenobarbital Clearance - Nonlinear Mixed Effects Modelling Approach Wednesday 10:20-11:50 |
I-44 Rasmus Juul Kildemoes How Repeated Time To Event (RTTE) modelling of opioid requests after surgery may improve future post-operative pain management Wednesday 10:20-11:50 |
I-45 Ana Novakovic Sample size calculations in multiple sclerosis using pharmacometrics methodology: comparison of a composite score continuous modeling and Item Response Theory approach Wednesday 10:20-11:50 |
I-46 Kristin Karlsson Estimating a Cox proportional hazard model in NONMEM Wednesday 10:20-11:50 |
I-47 Mats Karlsson Item response theory for analyzing placebo and drug treatment in Phase 3 studies of schizophrenia Wednesday 10:20-11:50 |
I-48 Takayuki Katsube Population PK/PD Modeling of Lusutrombopag, Thrombopoietin Receptor Agonist, in Healthy Volunteers for Exploring PK/PD Covariates Wednesday 10:20-11:50 |
I-49 Irene-Ariadne Kechagia A meta-analysis methodology to estimate population pharmacokinetic parameters from reported non-compartmental values with sparse sampling Wednesday 10:20-11:50 |
I-50 Ron Keizer Expected effectiveness of reduced-dose efavirenz Wednesday 10:20-11:50 |
I-51 David Khan Evaluation of Mechanism Based PKPD Model for Antibiotics Wednesday 10:20-11:50 |
I-52 Yukyung Kim Metformin's glucose lowering effect in healthy volunteers receiving an oral glucose tolerance test Wednesday 10:20-11:50 |
I-53 Yo Han Kim Early characterization of ticagrelor using modeling and simulation analysis of the in vitro platelet aggregation test and human pharmacokinetic data Wednesday 10:20-11:50 |
I-55 William Knebel Elastic Cloud Computing in Pharmacometrics: Usage Data and Strategies for Efficient Workflows Wednesday 10:20-11:50 |
I-56 Gilbert Koch Solving Semi-Delay Differential Equations in NONMEM Wednesday 10:20-11:50 |
I-57 Markus Krauß Hierarchical Bayesian-PBPK modeling for physiological characterization and extrapolation of patient populations from clinical data Wednesday 10:20-11:50 |
I-58 Mads Kreilgaard Study design optimization of a morphine analgesia trial using PKPD modelling and simulation Wednesday 10:20-11:50 |
I-59 Ryuji Kubota Population Pharmacokinetics of Ospemifene and Evaluation for Exposure Increase Wednesday 10:20-11:50 |